Mutations in the Cyclin-dependent kinase-like 5 (CDKL5) gene cause severe neurodevelopmental disorders accompanied by intractable epilepsies, i.e. West syndrome or atypical Rett syndrome. Here we report generation of the Cdkl5 knockout mouse and show that CDKL5 controls postsynaptic localization of GluN2B-containing N-methyl-d-aspartate (NMDA) receptors in the hippocampus and regulates seizure susceptibility. Cdkl5 -/Y mice showed normal sensitivity to kainic acid; however, they displayed significant hyperexcitability to NMDA. In concordance with this result, electrophysiological analysis in the hippocampal CA1 region disclosed an increased ratio of NMDA/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated excitatory postsynaptic currents (EPSCs) and a significantly larger decay time constant of NMDA receptor-mediated EPSCs (NMDA-EPSCs) as well as a stronger inhibition of the NMDA-EPSCs by the GluN2B-selective antagonist ifenprodil in Cdkl5 -/Y mice. Subcellular fractionation of the hippocampus from Cdkl5 -/Y mice revealed a significant increase of GluN2B and SAP102 in the PSD (postsynaptic density)-1T fraction, without changes in the S1 (post-nuclear) fraction or mRNA transcripts, indicating an intracellular distribution shift of these proteins to the PSD. Immunoelectron microscopic analysis of the hippocampal CA1 region further confirmed postsynaptic overaccumulation of GluN2B and SAP102 in Cdkl5 -/Y mice. Furthermore, ifenprodil abrogated the NMDA-induced hyperexcitability in Cdkl5 -/Y mice, suggesting that upregulation of GluN2B accounts for the enhanced seizure susceptibility. These data indicate that CDKL5 plays an important role in controlling postsynaptic localization of the GluN2B-SAP102 complex in the hippocampus and thereby regulates seizure susceptibility, and that aberrant NMDA receptor-mediated synaptic transmission underlies the pathological mechanisms of the CDKL5 loss-of-function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nbd.2017.07.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical studies of gene replacement therapy for CDKL5 deficiency disorder.
Mol Ther
October 2024
PTC Therapeutics, Inc, 500 Warren Corporate Center Drive, Warren, NJ 07059, USA. Electronic address:
Article Synopsis
- - CDD is a rare neurodevelopmental disorder linked to mutations in the CDKL5 gene, leading to symptoms like epilepsy, muscle weakness, and developmental delays.
- - Researchers created a gene therapy vector, AAV9.Syn.hCDKL5, to deliver the CDKL5 gene to the brain, using a specific promoter to enhance gene expression.
- - Studies in mice showed that injecting the vector directly into the cerebrospinal fluid improved distribution and resulted in biological activity, with successful functional improvements observed at higher doses.
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study.
Med
October 2024
Acadia Pharmaceuticals, Inc., San Diego, CA, USA. Electronic address:
Article Synopsis
- Trofinetide was shown to be effective for treating Rett syndrome in a long-term study called LILAC-2, following a shorter study, LAVENDER, confirming its benefits over 32 months.
- The study included 77 female participants aged 5-22, examining safety through adverse events and efficacy using specific rating scales, with diarrhea and COVID-19 being the most commonly reported side effects.
- Caregivers expressed high satisfaction with trofinetide, noting significant improvements in their children's symptoms without any new safety issues arising during the extended treatment.
Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study.
Med
September 2024
Acadia Pharmaceuticals Inc., San Diego, CA 92130, USA. Electronic address:
Article Synopsis
- Trofinetide, approved for treating Rett syndrome, showed continued efficacy and safety in the 40-week LILAC extension study following the initial 12-week LAVENDER trial.
- A total of 154 female participants aged 5-21 received trofinetide, with common side effects including diarrhea and vomiting; diarrhea was the leading cause for treatment withdrawal.
- Symptoms of Rett syndrome improved over the 40-week period, with no significant difference in safety profiles between LILAC and the previous LAVENDER study.
Enhanced hippocampal LTP but normal NMDA receptor and AMPA receptor function in a rat model of CDKL5 deficiency disorder.
Mol Autism
June 2024
Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.
Article Synopsis
- Mutations in the CDKL5 gene, associated with severe neurological disorders, lead to issues like early-onset epilepsy, autism, and intellectual disability, prompting this study to explore their impact on hippocampal function.
- Using a rat model with a specific loss of function mutation, the researchers conducted various electrophysiological and biochemical assessments to understand how the absence of CDKL5 affects synaptic behavior in the brain.
- The findings revealed enhanced long-term potentiation in juvenile Cdkl5 rats without altering NMDA receptor function or silent synapse formation, suggesting CDKL5 plays a crucial role in maintaining normal synaptic plasticity in the hippocampus.
Clinical and molecular heterogeneity in CDLK5 disorders.
Bol Med Hosp Infant Mex
July 2023
Departamento de Neurología Pediátrica, División de Pediatría. Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, México.
Background: CDKL5 deficiency syndrome is caused by pathogenic variants in the CDKL5 gene, with a variable clinical spectrum ranging from patients with characteristics of autism spectrum disorder to early-onset epilepsy refractory to treatment. Initially, until the gene was discovered, it was considered an atypical form of Rett syndrome. This study aimed to describe the clinical and molecular heterogeneity in CDLK5 disorders among three female patients with CDKL5 pathogenic variants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!